2019 - German National Academy of Sciences Leopoldina - Deutsche Akademie der Naturforscher Leopoldina – Nationale Akademie der Wissenschaften Internal Medicine and Dermatology
Gerhard Rogler mostly deals with Inflammatory bowel disease, Internal medicine, Immunology, Ulcerative colitis and Crohn's disease. His Inflammatory bowel disease study integrates concerns from other disciplines, such as Microbiome, Irritable bowel syndrome, Incidence, Pathophysiology and Colonoscopy. His Internal medicine study combines topics in areas such as Gastroenterology and Endocrinology.
His research investigates the connection between Ulcerative colitis and topics such as Primary sclerosing cholangitis that intersect with issues in Erythema nodosum, Pyoderma gangrenosum and Ankylosing spondylitis. In his study, Evidence-based medicine and Evidence-based practice is strongly linked to Intensive care medicine, which falls under the umbrella field of Crohn's disease. His work deals with themes such as Young adult and Surgery, which intersect with Disease.
Gerhard Rogler mainly investigates Internal medicine, Inflammatory bowel disease, Crohn's disease, Immunology and Ulcerative colitis. His work carried out in the field of Internal medicine brings together such families of science as Gastroenterology and Endocrinology. Gerhard Rogler interconnects Prospective cohort study, Azathioprine, Colitis and Intensive care medicine in the investigation of issues within Inflammatory bowel disease.
His Crohn's disease research is multidisciplinary, incorporating elements of Antibody and Surgery. His study involves Inflammation, Immune system, Tumor necrosis factor alpha, NOD2 and Pathogenesis, a branch of Immunology. His study explores the link between Ulcerative colitis and topics such as Infliximab that cross with problems in Adalimumab.
His primary scientific interests are in Internal medicine, Inflammatory bowel disease, Crohn's disease, Ulcerative colitis and Gastroenterology. His study in the field of Cohort study, Cohort and Tumor necrosis factor alpha also crosses realms of In patient. His study in Inflammatory bowel disease is interdisciplinary in nature, drawing from both Microbiome, Inflammation, Colitis, Immunology and Intensive care medicine.
His study with Crohn's disease involves better knowledge in Disease. His Ulcerative colitis research is multidisciplinary, incorporating perspectives in Adverse effect and Tofacitinib. His Gastroenterology research incorporates themes from Ingestion, Calprotectin and Gluten free.
Inflammatory bowel disease, Internal medicine, Crohn's disease, Ulcerative colitis and Gastroenterology are his primary areas of study. The study incorporates disciplines such as Tumor necrosis factor alpha, Inflammation, Colitis, Immunology and Cohort study in addition to Inflammatory bowel disease. His work in the fields of Odds ratio, Cohort, Proportional hazards model and Adverse effect overlaps with other areas such as In patient.
Gerhard Rogler has researched Crohn's disease in several fields, including Clinical trial, Surgery and Intensive care medicine. His Ulcerative colitis study integrates concerns from other disciplines, such as Microbiome, Bioinformatics, Gut flora, Tofacitinib and Drug. His study looks at the relationship between Gastroenterology and topics such as Abrilumab, which overlap with Moderate to severe, Multiple dose and Double blind.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis
Gert Van Assche;Axel Dignass;Julian Panes;Laurent Beaugerie.
Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion.
K Brand;S Page;G Rogler;A Bartsch.
Journal of Clinical Investigation (1996)
Nuclear factor κB is activated in macrophages and epithelial cells of inflamed intestinal mucosa
Gerhard Rogler;Korbinian Brand;Daniela Vogl;Sharon Page.
Cytokines in inflammatory bowel disease.
Gerhard Rogler;Tilo Andus.
World Journal of Surgery (1998)
Toll-like receptors 2 and 4 are up-regulated during intestinal inflammation
M. Hausmann;S. Kiessling;S. Mestermann;G. Webb.
Imaging techniques for assessment of inflammatory bowel disease: Joint ECCO and ESGAR evidence-based consensus guidelines
J. Panes;Y. Bouhnik;W. Reinisch;J. Stoker.
Journal of Crohn's and Colitis (2013)
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations.
Gert Van Assche;Axel Dignass;Bernd Bokemeyer;Silvio Danese.
Journal of Crohns & Colitis (2013)
3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 2: Surgical Management and Special Situations.
Paolo Gionchetti;Axel Dignass;Silvio Danese;Fernando José Magro Dias.
Journal of Crohns & Colitis (2017)
Probiotic Escherichia coli Nissle 1917 inhibits leaky gut by enhancing mucosal integrity.
Sya N. Ukena;Anurag Singh;Ulrike Dringenberg;Regina Engelhardt.
PLOS ONE (2007)
Frequency and Risk Factors for Extraintestinal Manifestations in the Swiss Inflammatory Bowel Disease Cohort
Stephan R Vavricka;Lionel Brun;Pierluigi Ballabeni;Valérie Pittet.
The American Journal of Gastroenterology (2011)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: